Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-614
- Development stage
- Phase 1
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABT-614 is a small molecule drug developed by Abbott Laboratories as a selective antagonist of the dopamine D3 receptor. It was investigated primarily for its potential therapeutic effects in metabolic and renal diseases, including type 2 diabetes with chronic kidney disease and albuminuria. The mechanism of action involves antagonism at the dopamine D3 receptor, which is implicated in various neuroendocrine and renal pathways. Clinical development reached Phase 1 trials, focusing on safety, tolerability, pharmacokinetics, and effects on glomerular filtration rate in patients with type 2 diabetes and chronic kidney disease[1][3][4].
- Other names
- ABT-614ABT614ABT 614
02
Targets
DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on ABT-614.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABT-614.